Skip to content

Diagnostic Performance of a Convolutional Neural Network for Diminutive Colorectal Polyp Recognition

Diagnostic Performance of a Convolutional Neural Network for Diminutive Colorectal Polyp Recognition. A Multicentre, Prospective Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03822390
Acronym
POLAR
Enrollment
292
Registered
2019-01-30
Start date
2018-10-16
Completion date
2021-10-16
Last updated
2021-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial Intelligence, Colorectal Polyp

Keywords

Artificial Intelligence, Computer aided diagnosis, Diminutive colorectal polyps, Optical diagnosis

Brief summary

Rationale: Diminutive colorectal polyps (1-5mm in size) have a high prevalence and very low risk of harbouring cancer. Current practice is to send all these polyps for histopathological assessment by the pathologist. If an endoscopist would be able to correctly predict the histology of these diminutive polyps during colonoscopy, histopathological examination could be omitted and practise could become more time- and cost-effective. Studies have shown that prediction of histology by the endoscopist remains dependent on training and experience and varies greatly between endoscopists, even after systematic training. Computer aided diagnosis (CAD) based on convolutional neural networks (CNN) may facilitate endoscopists in diminutive polyp differentiation. Up to date, studies comparing the diagnostic performance of CAD-CNN to a group of endoscopists performing optical diagnosis during real-time colonoscopy are lacking. Objective: To develop a CAD-CNN system that is able to differentiate diminutive polyps during colonoscopy with high accuracy and to compare the performance of this system to a group of endoscopist performing optical diagnosis, with the histopathology as the gold standard. Study design: Multicentre, prospective, observational trial. Study population: Consecutive patients who undergo screening colonoscopy (phase 2) Main study parameters/endpoints: The accuracy of optical diagnosis of diminutive colorectal polyps (1-5mm) by CAD-CNN system compared with the accuracy of the endoscopists. Histopathology is used as the gold standard.

Interventions

DEVICECAD-CNN system

The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).

Sponsors

Bergman Clinics
CollaboratorOTHER
Frisius Medisch Centrum
CollaboratorOTHER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

Phase 1A - \- Patients with one polyp subtype (based on histology) Phase 1B Patients older than 18 years that underwent colonoscopy in one of the participating centres. Phase 2:- Validation CAD-CNN system Inclusion Criteria: All patients older than 18 years old undergoing screenings colonoscopy in one of the participating centres.

Exclusion criteria

* Diagnosis of inflammatory bowel disease, Lynch syndrome or (serrated) polyposis syndrome. * Boston Bowel Preparation Scale (BBPS) \<2 in one of the colon segments * Patients who are unwilling or unable to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
The accuracy of the CAD-CNN system for predicting histology of diminutive colorectal polyps (1-5mm) compared with the accuracy of the prediction of the endoscopist. Both the CAD-CNN system and the endoscopist will use NBI for their predictions.2 yearAccuracy is defined as the percentage of correctly predicted optical diagnoses of the CAD-CNN system and / or endoscopist compared to the gold standard pathology. For the calculation of the accuracy, adenomas and SSLs will be dichotomized as neoplastic polyps, while HPs are considered non-neoplastic

Secondary

MeasureTime frameDescription
The mean number of attempts of the CAD-CNN to make a diagnosis per polyp2 yearThe mean number of attempts of the CAD-CNN to make a diagnosis per polyp
The ratio of unsuccessful diagnosis from all diagnosis of the CAD-CNN system. An unsuccessful diagnosis/failure of the CAD-CNN system is defined as more than 3 unsuccessful attempts2 yearThe ratio of unsuccessful diagnosis from all diagnosis of the CAD-CNN system. An unsuccessful diagnosis/failure of the CAD-CNN system is defined as more than 3 unsuccessful attempts
The number of diminutive polyps per colonoscopy that is resected and discarded without histopathological analysis with optical diagnosis strategy (the CAD-CNN system or endoscopist)2 yearThe number of diminutive polyps per colonoscopy that is resected and discarded without histopathological analysis with optical diagnosis strategy (the CAD-CNN system or endoscopist)
The percentage of colonoscopies in which diminutive polyps are characterized based on optical diagnosis, removed and discarded without histopathological evaluation (i.e. proportion of polyps assessed with high confidence)2 yearThe percentage of colonoscopies in which diminutive polyps are characterized based on optical diagnosis, removed and discarded without histopathological evaluation (i.e. proportion of polyps assessed with high confidence)
The percentage of colonoscopies in which the surveillance interval is based on the optical diagnosis of the CAD-CNN system and the patient can be directly informed of the surveillance interval after colonoscopy2 yearThe percentage of colonoscopies in which the surveillance interval is based on the optical diagnosis of the CAD-CNN system and the patient can be directly informed of the surveillance interval after colonoscopy
The percentage of colonoscopies in which diminutive hyperplastic polyps in the rectosigmoid are left in situ.2 yearThe percentage of colonoscopies in which diminutive hyperplastic polyps in the rectosigmoid are left in situ.
The mean duration in seconds of the CAD-CNN system to make a per polyp diagnosis.2 yearThe mean duration in seconds of the CAD-CNN system to make a per polyp diagnosis.
The diagnostic sensitiviy for optical diagnosis of the CAD-CNN system and the endoscopists2 yearThe diagnostic sensitiviy for optical diagnosis of the CAD-CNN system and the endoscopists
The accuracy rates on a per polyp basis2 yearAccuracy on a polyp basis is defined as the percentage of correctly predicted optical diagnoses of the CAD-CNN system and / or endoscopist compared to the gold standard pathology. For the calculation of the accuracy on a polyp basis, adenomas, SSLs and HPs are considered different subtypes.
Agreement between recommended surveillance intervals, based on optical diagnosis of diminutive polyps with high confidence, compared to surveillance recommendations based on histology of all polyps2 yearAgreement between recommended surveillance intervals, based on optical diagnosis of diminutive polyps with high confidence, compared to surveillance recommendations based on histology of all polyps
The diagnostic specificity for optical diagnosis of the CAD-CNN system and the endoscopists2 yearThe diagnostic specificity for optical diagnosis of the CAD-CNN system and the endoscopists
The diagnostic PPV for optical diagnosis of the CAD-CNN system and the endoscopists2 yearThe diagnostic PPV for optical diagnosis of the CAD-CNN system and the endoscopists
The diagnostic NPV for optical diagnosis of the CAD-CNN system and the endoscopists2 yearThe diagnostic NPV for optical diagnosis of the CAD-CNN system and the endoscopists
The diagnostic sensitivity for optical diagnosis of the CAD-CNN system and the endoscopists2 yearThe diagnostic sensitivity for optical diagnosis of the CAD-CNN system and the endoscopists

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 10, 2026